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Leukotriene B4 Mediates
Sphingosylphosphorylcholine-Induced
Itch-Associated Responses in Mouse Skin
Tsugunobu Andoh1, Ayumi Saito1 and Yasushi Kuraishi1
In atopic dermatitis, the concentration in the skin of sphingosylphosphorylcholine (SPC), which is produced
from sphingomyelin by sphingomyelin deacylase, is increased. In the present study, we investigated the itch-
eliciting activity of SPC and related substances and the mechanisms of SPC action in mice. An intradermal
injection of SPC, but not sphingomyelin and sphingosine, induced scratching, an itch-associated response,
which was not suppressed by a deficiency in mast cells or the H1 histamine receptor antagonist terfenadine. The
action of SPC was inhibited by the m-opioid receptor antagonist naltrexone. SPC action also was inhibited by the
5-lipoxygenase inhibitor zileuton and the leukotriene B4 antagonist ONO-4057, but not by the cyclooxygenase
inhibitor indomethacin. Moreover, SPC action was inhibited by the antiallergic agent azelastine, which
suppresses the action and production of leukotriene B4. Administration of SPC to the skin and to primary
cultures of keratinocytes increased leukotriene B4 production. SPC increased intracellular Ca
2þ ion
concentration in primary cultures of dorsal root ganglion neurons and keratinocytes. These results suggest
that SPC induces itching through a direct action on primary afferents and leukotriene B4 production of
keratinocytes. Sphingomyelin deacylase and SPC receptors may be previously unreported targets for
antipruritic drugs.
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INTRODUCTION
Pruritus is an essential symptom of atopic dermatitis, and the
suppression of itching (and scratching) is important in its
treatment. Although H1 histamine receptor antagonists are
often the drug of first choice for the treatment of itch, the
pruritus of atopic dermatitis responds poorly to them
(Wahlgren, 1991). The precise mechanisms and mediators
of itch in atopic dermatitis are unclear.
Dryness and impaired barrier function of the skin are
clinical signs of patients with atopic dermatitis. The amount
of ceramides is markedly reduced in the stratum corneum of
these patients (Imokawa et al., 1991; Okamoto et al., 2003).
Changes in the metabolism of ceramides have been believed
to be involved in dry skin and impaired barrier function in
atopic dermatitis. In healthy skin conditions, the amount of
ceramide in the stratum corneum is regulated by a balance of
the rate-limiting enzymes of sphingolipid synthesis, such as
serine-palmitoyl transferase, sphingomyelinase, and cerami-
dase. Ceramide is synthesized from sphingomyelin by
sphingomyelinase in the stratum corneum (Menon et al.,
1986). In the stratum corneum of atopic dermatitis patients,
sphingomyelin hydrolysis is due mainly to sphingomyelin
deacylase, which converts sphingomyelin into sphingosyl-
phosphorylcholine (SPC) and free fatty acid, rather than into
sphingomyelinase (Murata et al., 1996). The activity of
sphingomyelin deacylase is markedly higher in patients with
atopic dermatitis than in healthy individuals (Murata et al.,
1996; Hara et al., 2000), and SPC is increased in the stratum
corneum of atopic dermatitis (Okamoto et al., 2003).
However, there are conflicting reports regarding the role of
SPC in inflammation (Ceballos et al., 2007; Murch et al.,
2008), and the role of SPC in atopic dermatitis is unclear.
An intradermal injection of SPC elicits scratching, an itch-
associated response, in mice (Kim et al., 2008). SPC-induced
scratching was shown to be inhibited by an antagonist of G-
protein-coupled receptor 4, which had been reported to be
one of the SPC receptors (Sakai et al., 2005). Thereafter,
however, reports on the identification of G-protein-coupled
receptor 4 and ovarian cancer G-protein-coupled receptor 1
as SPC receptors (Xu et al., 2000; Zhu et al., 2001) were
retracted and an SPC receptor has not yet been identified. The
precise mechanisms of SPC-induced scratching remain
unclear, although the involvement of mast cells, capsaicin-
sensitive primary afferents, and Rho-associated protein kinase
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has been suggested (Kim et al., 2008). SPC acts on the
epidermal keratinocytes (Wakita et al., 1998). Recent studies
on peripheral mechanisms of itch have shown the important
role of keratinocytes and their itch mediators, including
leukotriene B4 (Andoh et al., 2001, 2004, 2007). Therefore,
this study investigated the involvement of leukotriene B4 and
histamine in SPC-induced scratching in mice.
RESULTS
Behavioral effects of SPC, sphingomyelin, and sphingosine
An intradermal injection of SPC (100 nmol per site) increased
scratching of the injected site by the hind paw, as compared
with vehicle; the effect had almost subsided by 60 minutes
(Figure 1a). SPC effects were dose dependent in the range of
10–100 nmol per site (Figure 1b). Intradermal injections of
sphingomyelin and sphingosine did not significantly increase
scratching (Figure 1b).
Effects of various agents on SPC-induced scratching
Effects of systemic pretreatment with several agents on
scratching induced by an intradermal injection of SPC
(100 nmol per site) were examined. The m-opioid receptor
antagonist naltrexone hydrochloride (1 mg kg1) significantly
inhibited SPC-induced scratching (Figure 2). The antiallergic
agent azelastine hydrochloride (3–30 mg kg1) produced a
dose-dependent inhibition of SPC-induced scratching, but the
H1 histamine receptor antagonist terfenadine (30 mg kg
1)
was without effect (Figure 3). The 5-lipoxygenase inhibitor
zileuton (30 and 100 mg kg1) and the leukotriene B4
receptor antagonist ONO-4057 (30 and 100 mg kg1) pro-
duced a dose-dependent inhibition of SPC-induced scratch-
ing, but the cyclooxygenase inhibitor indomethacin (3 and
10 mg kg1) was without effect (Figure 4).
Effect of mast cell deficiency on SPC-induced scratching
Deficiency in mast cells did not affect scratching induced by
an intradermal injection of SPC (100 nmol per site); scratch
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Figure 1. Scratching after intradermal injections of
sphingosylphosphorylcholine (SPC) and related substances. Mice were given
an intradermal injection and scratching was counted for 60 minutes. (a) Time
course of scratching after vehicle (VH, upper panel) and SPC (lower panel,
100 nmol per site) injection. (b) Dose–response curves for SPC (circles),
sphingomyelin (squares), and sphingosine (triangles). Values represent the
means±SEM for eight animals. *Po0.05 when compared with VH (Dunnett’s
multiple comparisons).
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Figure 2. Suppression by naltrexone of sphingosylphosphorylcholine (SPC)-
induced scratching. Mice were given an intradermal injection of SPC
(100 nmol per site) and scratching was counted for 1 hour. Naltrexone
hydrochloride (1 mg kg1) or vehicle (saline) was injected subcutaneously
15 minutes before intradermal injection. Values represent the means±SEM
for eight animals. *Po0.05 when compared with vehicle (Student’s t-test).
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Figure 3. Effects of azelastine and terfenadine on scratching induced by
sphingosylphosphorylcholine (SPC). Mice were given an intradermal
injection of SPC (100 nmol per site) and scratching was counted for 1 hour.
Azelastine hydrochloride, terfenadine, and vehicle (VH) were administered
orally 1 hour before SPC injection. Values represent the means±SEM for eight
animals. *Po0.05 when compared with VH (Dunnett’s multiple comparisons
or Student’s t-test).
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bouts for 1 hour were 348±32 and 354±69 (mean±SEM,
n¼8 each) in WBB6F1 W/W v and the control WBB6F1þ /þ
mice, respectively.
SPC-induced production of leukotriene B4
An intradermal injection of SPC (100 nmol per site) increased
the concentration of leukotriene B4 in the treated skin, which
was almost abolished by zileuton (100 mg kg1) (Figure 5a). A
bath application of SPC at a concentration of 200 mM, but not
2–20 mM, to primary cultures of mouse keratinocytes signifi-
cantly increased the production of leukotriene B4 (Figure 5b).
The effect of SPC (200mM) was almost abolished by zileuton
(10 mM) (Figure 5c).
SPC-induced increase in intracellular Ca2þ concentration in
dorsal root ganglion neurons and keratinocytes
Sphingosylphosphorylcholine at a concentration of 200 mM,
but not 20mM, markedly increased the concentration of
intracellular Ca2þ ions in the cultured keratinocytes; the
effect peaked around 20 seconds after administration and had
almost subsided by 40 seconds (Figure 6a). In primary
cultures of dorsal root ganglion (DRG) neurons, SPC at 20
and 200mM produced a marked concentration-dependent
increase in the concentration of intracellular Ca2þ ions; the
effect peaked around 20 seconds after administration and had
almost subsided by 120 seconds (Figure 6b).
DISCUSSION
Sphingomyelin is metabolized to SPC and ceramide by
sphingomyelin deacylase and sphingomyelinase, respec-
tively. Ceramide is further metabolized to sphingosine by
ceramidase. In this study, SPC, sphingomyelin, and sphingo-
sine were administered to the mouse skin and only SPC
significantly elicited scratching, an itch-related behavior,
suggesting that SPC, but not sphingomyelin and sphingosine,
is an endogenous itch mediator. As the activity of sphingo-
myelin deacylase is very low in healthy skin (Hara et al.,
2000), substantial amounts of SPC might not be produced
from sphingomyelin after its intradermal administration.
SPC-induced scratching was inhibited by the m-opioid
receptor antagonist naltrexone. This result is similar to the
observation by another group (Kim et al., 2008). Opioid
antagonists have been shown to inhibit scratching induced by
several pruritogens (Andoh et al., 1998b, 2004; Yamaguchi
et al., 1999), immediate allergy (Ohtsuka et al., 2001),
chronic dermatitis (Yamaguchi et al., 2001), and xerosis
(Miyamoto et al., 2002). Opioid antagonists have also been
shown to alleviate the itch of patients with pruritic diseases
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Figure 4. Effects of inhibition of eicosanoid systems on scratching induced
by sphingosylphosphorylcholine (SPC). Mice were given an intradermal
injection of SPC (100 nmol per site) and scratching was counted for 1 hour.
Zileuton, ONO-4057, indomethacin, and vehicle (VH) were administered
orally 1 hour before SPC injection. Values represent the means±SEM for eight
animals. *Po0.05 when compared with VH (Dunnett’s multiple
comparisons).
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Figure 5. Sphingosylphosphorylcholine (SPC)-induced production of
leukotriene B4 in the skin and cultured keratinocytes. (a) LTB4 production in
the skin. Mice were given an intradermal injection of SPC (100 nmol per site)
or vehicle (VH1: 1% ethanol in saline) and the concentration of LTB4 in the
treated skin was determined 10 minutes later. Zileuton (100 mg kg1) and
vehicle (VH2: 0.5% carboxymethyl cellulose) were administered orally 1 hour
before SPC injection. Values represent the means±SEM for eight animals.
*Po0.05 when compared with VH1þVH2. #Po0.05 when compared with
VH2þ SPC. (b) Concentration dependence of SPC-induced LTB4 production
of the keratinocytes. SPC was administered to cultured keratinocytes, and
LTB4 concentration in the cultured medium was determined 10 minutes
later. *Po0.05 when compared with control. (c) Inhibition by zileuton of
SPC-induced LTB4 production of the keratinocytes. LTB4 concentration was
determined 10 minutes after the administration of SPC (200 mM) and vehicle
(VH3: 0.1% dimethyl sulfoxide). Zileuton (10 mM) and vehicle (VH4: 0.1%
dimethyl sulfoxide) were applied 1 hour before SPC administration. Values
represent the means±SEM for six wells. *Po0.05 when compared with
VH3þVH4. #Po0.05 when compared with VH4þ SPC. Statistical
significance was determined by Dunnett’s multiple comparisons.
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such as cholestasis, chronic urticaria, and atopic dermatitis
(Monroe, 1989; Bergasa et al., 1995). Opioid antagonists may
inhibit itching and scratching through action on m-opioid
receptors in the central nervous system, especially in the
lower brainstem (Thomas et al., 1993; Tohda et al., 1997;
Andoh et al., 2008; Kuraishi et al., 2008). With these findings
being taken into account, it is suggested that SPC-induced
scratching is an itch-associated response.
SPC-induced scratching was inhibited by the 5-lipoxygen-
ase inhibitor zileuton and the leukotriene B4 antagonist
ONO-4057, but not by the cyclooxygenase inhibitor
indomethacin. Considering the findings that an intradermal
injection of leukotriene B4, but not prostaglandin E2, elicits
scratching in mice (Andoh and Kuraishi, 1998), the present
results suggest that leukotriene B4 has an important role in
SPC-induced scratching. The idea is supported by the results
that a pruritogenic dose of SPC increased the cutaneous
concentration of leukotriene B4, which was blocked by
zileuton. Azelastine (3–30 mg kg1) produced a marked
inhibition of SPC-induced scratching. This effect may be
mediated by the blockade of leukotriene B4 action, because
the same doses exert an inhibitory effect on leukotriene B4-
induced scratching (Andoh and Kuraishi, 2002). Because
azelastine suppresses the production of leukotriene B4
(Taniguchi et al., 1990; Shimizu et al., 1995; Andoh and
Kuraishi, 2002), this suppression may be partly involved in
the inhibition of SPC-induced scratching.
Administration of SPC to cultured keratinocytes increased
the production of leukotriene B4, suggesting that epidermal
keratinocytes are important for SPC-induced leukotriene B4
production in the skin. In the stratum corneum of atopic
dermatitis, sphingomyelin is hydrolyzed to SPC with sphin-
gomyelin deacylase rather than to ceramide with sphingo-
myelinase (Murata et al., 1996). In the stratum corneum of
lesional skin, the activity of sphingomyelin deacylase is
markedly higher in the lower layers than in the upper layers
(Murata et al., 1996) and is higher in the whole epidermis
than in the stratum corneum (Hara et al., 2000). Taken
together, these findings suggest that the activity of sphingo-
myelin deacylase and the production of SPC are increased in
the epidermal keratinocytes of the lesional skin of atopic
dermatitis. Thus, keratinocytes may be important sources of
SPC, and SPC may act in an autocrine or paracrine manner to
produce itch-associated mediators such as SPC itself and
leukotriene B4.
SPC increased intracellular Ca2þ ions in primary cultures
of mouse keratinocytes. There are at least two possible
pathways for keratinocytes to produce leukotriene B4 after
SPC stimulation. One is the activation of phospholipase A2
through the increase in intracellular free Ca2þ ions induced
by SPC (Clark et al., 1990; Shirao et al., 2002). Another
pathway is Rho kinase-mediated phospholipase A2 activation
(Chen et al., 2008). Scratching induced by intradermal SPC is
inhibited by LY-2732, a Rho kinase inhibitor (Kim et al.,
2008), which may be partly due to the inhibition of Rho
kinase–mediated production of leukotriene B4, because Rho
kinase has no effect on leukotriene B4 receptor–mediated
signaling (Sabirsh et al., 2004).
Two leukotriene B4 receptors, BLT1 and BLT2, have been
cloned (Yokomizo et al., 1997, 2000). These receptors have
higher and lower binding affinities for leukotriene B4,
respectively, and are both G-protein-coupled (Yokomizo
et al., 1997, 2000). BLT1, but not BLT2, receptor is present in
primary sensory neurons (Andoh and Kuraishi, 2005). Many
BLT1-positive neurons express transient receptor potential
vanilloid 1 (TRPV1) channels and respond to capsaicin
(Andoh and Kuraishi, 2005). Capsaicin-sensitive primary
afferents have an important role in itch signaling (Andoh
et al., 1998b; Yamaguchi et al., 1999; Nakano et al., 2008).
BLT1 receptor activation increases the intracellular concen-
tration of inositol 1,4,5-triphosphate, which leads to Ca2þ
release from intracellular stores and then Ca2þ influx
(Yokomizo et al., 1997; Sabirsh et al., 2004). This intracel-
lular signaling may sensitize TRPV1 channels (Clapham et al.,
2005). Although efficacy is low, leukotriene B4 directly
activates TRPV1 channels (Hwang et al., 2000). Taken
together, these findings suggest that TRPV1 channels play a
role in leukotriene B4-associated itch. BLT1, but not BLT2,
receptor mRNA is expressed in the skin (Andoh and Kuraishi,
2005), and leukotriene B4 acts on the epidermal keratinocytes
(Kragballe et al., 1985). Although it remains unclear whether
leukotriene B4 acts on the keratinocytes to produce and/or
release itch-associated mediators, such as nitric oxide (Andoh
and Kuraishi, 2003), thromboxane A2 (Andoh et al., 2007),
and nociceptin (Andoh et al., 2004), it is possible that
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Figure 6. Sphingosylphosphorylcholine (SPC) acts on keratinocytes and
dorsal root ganglion neurons to increase intracellular Ca2+ ions. (a)
Keratinocytes and (b) dorsal root ganglion neurons. Left graphs, typical
examples of changes after the administration of SPC (200 mM). Right graphs,
maximal change after SPC administration in the keratinocytes (n¼ 16–23) and
dorsal root ganglion neurons (n¼ 8–29). The primary cultures were preloaded
with fluo-3. Values represent the means±SEM. *Po0.05 when compared
with vehicle (VH).
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keratinocytes are also involved in leukotriene B4–associated
itching.
SPC-induced scratching was not inhibited by the H1
histamine receptor antagonist terfenadine at the dosage that
inhibits scratching induced by histamine and mast cell
degranulation (Inagaki et al., 1999; Ohtsuka et al., 2001).
In addition, SPC-induced scratching was not affected by
deficiency in mast cells. These results suggest that the mast
cell and its mediator histamine do not have a key role in SPC-
induced scratching. SPC-induced scratching was, however,
shown to be inhibited by ketotifen at an intravenous dose of
1 mg kg1 (Kim et al., 2008). These findings are not
incompatible with the above idea, because the oral dose
(1 mg kg1) of this agent markedly inhibits plasma extravasa-
tion induced by histamine and passive cutaneous reaction
(Ueno et al., 1998), but it does not inhibit SPC-induced
scratching (Kim et al., 2008). The inhibition effect of ketotifen
may be due partly to the suppression of leukotriene B4
production (Matsushita et al., 1998).
The frequency of SPC-induced scratching in ICR mice was
roughly similar between these experiments and those of
another group (Kim et al., 2008), but the frequency of
scratching in WBB6F1 mice was clearly higher than that in
ICR mice. One possible explanation for the strain difference
is that the expression levels of SPC receptors in the
keratinocytes and itch-associated primary afferents are higher
in WBB6F1 mice than in ICR mice. However, SPC receptors
have not been identified, as mentioned in the Introduction,
and verification should wait for the clear identification of the
SPC receptor. In contrast to SPC, scratch responses to
histamine and serotonin were clearly larger in ICR mice than
in WBB6F1 mice (Inagaki et al., 2001). The frequency of
scratching induced by substance P is similar between ICR and
WBB6F1 mice (Andoh et al., 1998b). Therefore, the
difference in behavioral response to SPC may not be due to
strain differences in behavioral reactivity.
SPC increased intracellular Ca2þ ions in primary cultures
of mouse DRG neurons, suggesting the direct action of SPC
on primary afferents. SPC-induced scratching was slow in
onset and long in duration, whereas the effect of SPC on the
DRG neurons was relatively short in duration. Capsaicin-
sensitive primary afferents expressing TRPV1 channels may
play a role in itch signaling (Kim et al., 2008; Nakano et al.,
2008). The sensitization of Gq/11-coupled receptors of
primary sensory neurons (for example, by adenosine
50-triphosphate and bradykinin) results in the sensitization
of TRPV1 channels through the increase in intracellular Ca2þ
ions and the activation of protein kinase C (Story, 2006).
Thus, we speculate that SPC increases intracellular Ca2þ ions
to sensitize TRPV1 channels of itch-signaling primary
afferents.
Ceramides have an essential role in the barrier and water-
holding functions of the stratum corneum (Imokawa et al.,
1989, 1994). In normal conditions, the ceramide content
in the stratum corneum is regulated by the production
from sphingomyelin and glucosylceramide by sphingo-
myelinase and b-glucocerebrosidase, respectively, and the
degradation to sphingosine by ceramidase (Imokawa, 2001).
Sphingomyelin hydrolysis activity and ceramides are
markedly increased and decreased, respectively, in the
stratum corneum of atopic dermatitis (Imokawa et al., 1991;
Murata et al., 1996). The increase in the sphingomyelin
hydrolysis activity is due mainly to the increase in metabo-
lism of sphingomyelin to SPC by sphingomyelin deacylase
(Hara et al., 2000), which probably leads to the decrease in
the production of ceramides from sphingomyelin. This study
showed that SPC, but neither sphingomyelin nor sphingosine,
induced itch-related behaviors in mice. Thus, alterations in
sphingomyelin metabolism, namely, decrease in ceramides
and increase in SPC, cause dysfunction of barrier and water-
holding of the skin and itching, respectively. SPC may induce
an itch through action on the keratinocytes to produce
leukotriene B4 and on the primary afferents. Leukotriene B4,
increased in the skin by atopic dermatitis (Fogh et al., 1989),
also acts on the primary afferents and keratinocytes (Andoh
and Kuraishi, 2005). The autocrine or paracrine actions of
SPC and leukotriene B4 may augment itching of atopic
dermatitis.
MATERIALS AND METHODS
Animals
Male ICR mice (5–9 weeks old or neonatal) were used, except in one
experiment in which mast cell–deficient WBB6F1 W/Wv mice
(6 weeks old) and the normal WBB6F1 þ /þ littermates were used,
all purchased from Japan SLC (Shizuoka, Japan). The mice were
housed in a room under controlled temperature (22±1 1C), humidity
(55±10%), and light (lights on from 0700 to 1900 hours). Food and
water were freely available. Procedures used in the animal
experiments were approved by the Committee for Animal Experi-
ments at the University of Toyama.
Materials
For in vivo experiments, SPC, sphingomyelin, and sphingosine (all
purchased from Sigma, St Louis, MO) were dissolved in physiolo-
gical saline containing 1% ethanol. These agents were injected
intradermally into the interscapular region in a volume of 50 ml.
For in vitro experiments, SPC, zileuton, and indomethacin were
dissolved in mouse keratinocyte growth medium containing 0.1%
DMSO. Naltrexone hydrochloride (Sigma) was dissolved in physio-
logical saline and injected subcutaneously 15 minutes before SPC
injection. Azelastine hydrochloride was dissolved in tap water and
administered orally 30 minutes before SPC injection. Tefenadine,
tranilast, zileuton, indomethacin, and ONO-4057 (5-[2-(2-carbox-
yethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl]oxyphenoxy] valeric
acid) were dissolved in 0.5% sodium carboxymethyl cellulose
(Wako Pure Chemical Industries, Osaka, Japan). These agents were
administered orally 1 hour before SPC injection.
Behavioral experiments
The day before the experiment, the hair was clipped over the rostral
part of the back of 5- or 9-week-old mice. Before behavioral
observation, the animals were put individually in an acrylic cage
composed of four cells (13 9 35 cm) for at least 1 hour for
acclimation. Immediately after intradermal or subcutaneous injec-
tion, the animals were put back into the same cells and their
behaviors were videotaped for 1 hour with personnel kept out of the
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observation room. Playback of the videotape served for the
determination of scratching of the rostral back or licking of the hind
paw (Kuraishi et al., 1995).
Cell culture
The bilateral DRG at the C1–T13 levels were removed from 6-week-
old mice. The cells were dissociated with 0.25% collagenase (Wako
Pure Chemical Industries) and cultured in DMEM (Invitrogen,
Carlsbad, CA) containing 10% heat-inactivated fetal bovine serum
and 2mM cytosine arabinoside (Sigma), which kills glial cells, for at
least 7 days.
To prepare keratinocytes, the skin was removed from neonatal
mice and treated with 0.05% collagenase A (Roche Diagnostics
GmbH, Mannheim, Germany) dissolved in mouse keratinocyte
growth medium at 4 1C overnight. The keratinocyte samples were
cultured in mouse keratinocyte growth medium containing 5 mg ml1
insulin, 0.5mg ml1 hydrocortisone, 14.1mg ml1 phosphorylethano-
lamine, 0.01 mg ml1 epidermal growth factor, 10 mg ml1 transferrin,
and 0.1 mg ml1 bovine pituitary extract (Andoh et al., 2007).
Measurement of intracellular Ca2þ concentration
Primary cultures of DRG neurons and keratinocytes were washed
with the medium Opti-MEM (Invitrogen), incubated with 10 mM fluo-
3/AM (Dojindo, Kumamoto, Japan) in Opti-MEM containing 0.05%
poloxamer (Calbiochem, Darmstadt, Germany), and then washed
with Opti-MEM. Intracellular Ca2þ concentration was measured
fluorometrically at 488 nm excitation and 515–545 nm emission
using a laser-scanning microscope system (Radiance 2100; Bio-Rad,
Hercules, CA). Although SPC receptors have not been identified, the
action of SPC is inhibited by pretreatment with capsaicin (Kim et al.,
2008), suggesting that SPC acts on capsaicin-sensitive primary
sensory neurons. Most of the small and medium-sized neurons
(p25 mm in diameter) are capsaicin-sensitive (Andoh et al., 1998a).
Therefore, DRG neurons p25 mm in diameter were used in this
experiment. Neuronal diameter was determined using bright-field
microscopy with an objective micrometer (Nikon, Tokyo, Japan).
Trypan blue exclusion test confirmed the absence of any apparent
damage to the cultured cells after 10-minute administration of SPC.
Enzyme immunoassay for LTB4
The SPC-injected region of the skin (1.7 cm in diameter) was
removed 10 minutes after injection. After being weighed, the skin
was immediately shredded with scissors and put into 2 ml of ice-
chilled ethanol containing 10 mM indomethacin and 10 mM zileuton.
After being homogenized with a Polytron homogenizer, the sample
was centrifuged at 2,000 r.p.m. at 4 1C for 5 minutes. One milliliter of
the supernatant was mixed with 5 ml of double-distilled water and
the pH was adjusted to 3.5 with HCl. The sample was then applied
to C18 Sep-Pak cartridges (Waters, Milford, MA) equilibrated with
methanol. After the cartridges were washed with hexane followed by
double-distilled water, the lipids were eluted with ethanol. After
evaporation of the eluate, the residue was suspended in enzyme
immunoassay buffer (Cayman Chemical, Ann Arbor, MI) for the
assay of LTB4. In the case of cultured keratinocytes, the culture
medium was changed to mouse keratinocyte growth medium before
experimentation. Samples were taken from the supernatant 10 min-
utes after SPC administration and served for the assay of LTB4. The
amount of LTB4 was determined using EIA kits (Cayman Chemical).
After supernatant sampling, cultured keratinocytes were treated with
1% Triton X-100 to solubilize the cell proteins, the concentration of
which was determined using a Bio-Rad protein assay kit (Bio-Rad).
The concentration of LTB4 in the skin and keratinocytes was
normalized to skin weight and protein amount, respectively.
Data processing
Data are presented as means±SEM. Statistical significance was
analyzed using Dunnett’s multiple comparisons or Student’s t-test;
*Po0.05 was considered significant.
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